Overview

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter phase 2 open-label single-arm study that will evaluate the safety and efficacy of TAK-700 in patients with castration-resistant prostate cancer (CRPC) without radiographic evidence of metastases who have a rising prostate-specific antigen (PSA).
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.